Ehab L. Atallah, MD, on AML and COVID-19: Expert Guidance on Administering Venetoclax and TKIs

Posted: Tuesday, May 12, 2020

Ehab L. Atallah, MD, of the Medical College of Wisconsin, talks about whether, during the COVID-19 pandemic, patients with acute myeloid leukemia should continue targeted treatments such as venetoclax or tyrosine kinase inhibitors, which may cause adverse effects to the lungs.